Blocking prokineticin receptors attenuates synovitis and joint destruction in collagen-induced arthritis.
Prokineticin 2
Prokineticin receptor antagonists
Prokineticin receptors
Type II collagen–induced arthritis (CIA)
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
17
10
2022
accepted:
14
03
2023
revised:
09
02
2023
medline:
8
5
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
Rheumatoid arthritis (RA) is a chronic inflammatory disease mediated by an interdependent network of proinflammatory molecules such as chemokines. Prokineticin 2 (PK2) is a chemokine-like peptide that modulates nociceptive threshold and immuno-inflammatory processes via two G-protein-linked receptors, prokineticin receptor 1 and 2 (PKR1 and PKR2). In the present study, we investigated the effects of the prokineticin receptor antagonist PC1 on arthritic pain and the inflammatory response in type II collagen-induced arthritis (CIA) in mice. We demonstrated that PC1, administered subcutaneously from day 25 to day 35 after CIA, improved clinical signs of arthritis such as paw edema, pain, and impaired locomotor activity. In CIA mice, PC1 was also able to lower plasma malondialdehyde (MDA) levels, suggesting a role in reducing oxidative damage, as well as joint expression levels of PK2, PKRs, TNFα, IL-1β, CD4, CD8, and NF-kB. These results suggest that blocking PKRs may be a successful strategy to control arthritic pain and pathology development. KEY MESSAGES: PK2/PKRs expression levels strongly increase in the synovium of RA mice. PC1 treatment shows anti-arthritic activity and reduces arthritis-induced pain. PC1 treatment significantly lowers synovial PK2/PKRs levels. PC1 treatment lowers plasma MDA levels and synovial levels of TNFα and IL -1β PC1 treatment is a viable therapeutic option for RA.
Identifiants
pubmed: 36988653
doi: 10.1007/s00109-023-02307-6
pii: 10.1007/s00109-023-02307-6
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-580Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Emery P, Buch M (2002) Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. BMJ 324:312–313. https://doi.org/10.1136/bmj.324.7333.312
doi: 10.1136/bmj.324.7333.312
pubmed: 11834544
pmcid: 1122253
Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108. https://doi.org/10.1016/s0140-6736(10)60826-4
doi: 10.1016/s0140-6736(10)60826-4
pubmed: 20870100
Andersson MLE, Svensson B, Bergman S (2013) Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol 40:1977–1985. https://doi.org/10.3899/jrheum.130493
doi: 10.3899/jrheum.130493
pubmed: 24187108
Shelef MA (2019) New relationships for old autoantibodies in rheumatoid arthritis. Arthritis Rheumatol 71:1396–1399. https://doi.org/10.1002/art.40879
doi: 10.1002/art.40879
pubmed: 30861623
pmcid: 6716984
Elemam NM, Hannawi S, Maghazachi AA (2020) Role of chemokines and chemokine receptors in rheumatoid arthritis. Immunotargets Ther 9:43–56. https://doi.org/10.2147/itt.S243636
doi: 10.2147/itt.S243636
pubmed: 32211348
pmcid: 7074856
Kondo N, Kuroda T, Kobayashi D (2021) Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci 22(20):10922. https://doi.org/10.3390/ijms222010922
doi: 10.3390/ijms222010922
pubmed: 34681582
pmcid: 8539723
Fang Q, Zhou C, Nandakumar KS (2020) Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators Inflamm 2020:3830212. https://doi.org/10.1155/2020/3830212
doi: 10.1155/2020/3830212
pubmed: 32256192
pmcid: 7103059
Negri L, Lattanzi R (2011) Bv8-prokineticins and their receptors: modulators of pain. Curr Pharma Biotechnol 12:1720–1727. https://doi.org/10.2174/138920111798357410
Negri L, Ferrara N (2018) The prokineticins: neuromodulators and mediators of inflammation
Negri L, Maftei D (2018) Targeting the prokineticin system to control chronic pain and inflammation. Curr Med Chem 25:3883–3894. https://doi.org/10.2174/0929867324666170713102514
Maftei D, Vellani V, Artico M, Giacomoni C, Severini C, Lattanzi R (2020) Abnormal pain sensation in mice lacking the prokineticin receptor PKR2: interaction of PKR2 with transient receptor potential TRPV1 and TRPA1. Neurosci 427:16–28. https://doi.org/10.1016/j.neuroscience.2019.12.003
Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, Negri L, Sacerdote P (2006) Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol 147:225–234. https://doi.org/10.1038/sj.bjp.0706467
doi: 10.1038/sj.bjp.0706467
pubmed: 16299550
Franchi S, Giannini E, Lattuada D, Lattanzi R, Tian H, Melchiorri P, Negri L, Panerai AE, Sacerdote P (2008) The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunol 9:60. https://doi.org/10.1186/1471-2172-9-60
doi: 10.1186/1471-2172-9-60
pubmed: 18957080
pmcid: 2584092
Severini C, Lattanzi R, Maftei D, Marconi V, Ciotti MT, Petrocchi Passeri P, Florenzano F, Del Duca E, Caioli S, Zona C et al (2015) Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity. Sci Rep 5:15301. https://doi.org/10.1038/srep15301
doi: 10.1038/srep15301
pubmed: 26477583
pmcid: 4610025
Caioli S, Severini C, Ciotti T, Florenzano F, Pimpinella D, Petrocchi Passeri P, Balboni G, Polisca P, Lattanzi R, Nisticò R et al (2017) Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer’s disease. Neuropharmacology 116:82–97. https://doi.org/10.1016/j.neuropharm.2016.12.012
doi: 10.1016/j.neuropharm.2016.12.012
pubmed: 27989680
Lattanzi R, Maftei D, Petrella C, Pieri M, Sancesario G, Schirinzi T, Bernardini S, Barbato C, Ralli M, Greco A et al (2019a) Involvement of the chemokine prokineticin-2 (PROK2) in Alzheimer’s disease: from animal models to the human pathology. Cells 8. https://doi.org/10.3390/cells8111430
Lattanzi R, Maftei D, Fullone MR, Miele R (2019) Identification and characterization of prokineticin receptor 2 splicing variant and its modulation in an animal model of Alzheimer’s disease. Neuropeptides 73:49–56. https://doi.org/10.1016/j.npep.2018.11.006
doi: 10.1016/j.npep.2018.11.006
pubmed: 30553543
Maftei D, Ratano P, Fusco I, Marconi V, Squillace S, Negri L, Severini C, Balboni G, Steardo L, Bronzuoli MR et al (2019) The prokineticin receptor antagonist PC1 rescues memory impairment induced by β amyloid administration through the modulation of prokineticin system. Neuropharmacol 158:107739. https://doi.org/10.1016/j.neuropharm.2019.107739
Schirinzi T, Maftei D, Pieri M, Bernardini S, Mercuri NB, Lattanzi R, Severini C (2021) Increase of prokineticin-2 in serum of patients with Parkinson’s disease. Mov Disord 36:1031–1033. https://doi.org/10.1002/mds.28458
doi: 10.1002/mds.28458
pubmed: 33404134
Lattanzi R, Miele R (2021) Versatile role of prokineticins and prokineticin receptors in neuroinflammation. Biomedicines 9:1648. https://doi.org/10.3390/biomedicines9111648
doi: 10.3390/biomedicines9111648
pubmed: 34829877
pmcid: 8615546
Cheng MY, Leslie FM, Zhou QY (2006) Expression of prokineticins and their receptors in the adult mouse brain. J Comp Neurol 498:796–809. https://doi.org/10.1002/cne.21087
doi: 10.1002/cne.21087
pubmed: 16927269
pmcid: 2667319
Negri L, Lattanzi R, Giannini E, Melchiorri P (2006) Modulators of pain: Bv8 and prokineticins. Curr Neuropharmacol 4:207–215. https://doi.org/10.2174/157015906778019518
doi: 10.2174/157015906778019518
pubmed: 18615143
pmcid: 2430691
Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P, Screpanti I, Balboni G, Salvadori S, Sacerdote P, Negri L (2009) The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A 106:14646–14651. https://doi.org/10.1073/pnas.0903720106
doi: 10.1073/pnas.0903720106
pubmed: 19667192
pmcid: 2731841
Kurosaka D, Noda K, Yoshida K, Furuya K, Ukichi T, Takahashi E, Yanagimachi M, Kingetsu I, Saito S, Yamada A (2009) Elevation of Bombina variegata peptide 8 in mice with collagen-induced arthritis. BMC Musculoskelet Disord 10:45. https://doi.org/10.1186/1471-2474-10-45
doi: 10.1186/1471-2474-10-45
pubmed: 19405944
pmcid: 2687415
Ito H, Noda K, Yoshida K, Otani K, Yoshiga M, Oto Y, Saito S, Kurosaka D (2016) Prokineticin 2 antagonist, PKRA7 suppresses arthritis in mice with collagen-induced arthritis. BMC Musculoskelet Disord 17:387. https://doi.org/10.1186/s12891-016-1243-0
doi: 10.1186/s12891-016-1243-0
pubmed: 27609223
pmcid: 5016855
Noda K, Dufner B, Ito H, Yoshida K, Balboni G, Straub RH (2021) Differential inflammation-mediated function of prokineticin 2 in the synovial fibroblasts of patients with rheumatoid arthritis compared with osteoarthritis. Sci Rep 11:18399. https://doi.org/10.1038/s41598-021-97809-z
doi: 10.1038/s41598-021-97809-z
pubmed: 34526577
pmcid: 8443611
Balboni G, Lazzari I, Trapella C, Negri L, Lattanzi R, Giannini E, Nicotra A, Melchiorri P, Visentin S, Nuccio CD, Salvadori S (2008) Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem 51:7635–7639. https://doi.org/10.1021/jm800854e
doi: 10.1021/jm800854e
pubmed: 19006379
Maftei D, Marconi V, Florenzano F, Giancotti LA, Castelli M, Moretti S, Borsani E, Rodella LF, Balboni G, Luongo L et al (2014) Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals. Br J Pharmacol 171:4850–4865. https://doi.org/10.1111/bph.12793
doi: 10.1111/bph.12793
pubmed: 24902717
pmcid: 4294109
Lattanzi R, Maftei D, Marconi V, Florenzano F, Franchi S, Borsani E, Rodella LF, Balboni G, Salvadori S, Sacerdote P et al (2015) Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model. Biomed Res Int 2015:301292. https://doi.org/10.1155/2015/301292
Guida F, Lattanzi R, Boccella S, Maftei D, Romano R, Marconi V, Balboni G, Salvadori S, Scafuro MA, de Novellis V et al (2015) PC1, a non-peptide PKR1-preferring antagonist, reduces pain behavior and spinal neuronal sensitization in neuropathic mice. Pharmacol Res 91:36–46. https://doi.org/10.1016/j.phrs.2014.11.004
doi: 10.1016/j.phrs.2014.11.004
pubmed: 25434589
Castelli M, Amodeo G, Negri L, Lattanzi R, Maftei D, Gotti C, Pistillo F, Onnis V, Congu C, Panerai AE et al (2016) Antagonism of the prokineticin system prevents and reverses allodynia and inflammation in a mouse model of diabetes. PLoS One 11:e0146259. https://doi.org/10.1371/journal.pone.0146259
Moschetti G, Amodeo G, Maftei D, Lattanzi R, Procacci P, Sartori P, Balboni G, Onnis V, Conte V, Panerai A et al (2019) Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. J Neuroinflammation 16:89. https://doi.org/10.1186/s12974-019-1461-0
doi: 10.1186/s12974-019-1461-0
pubmed: 30995914
pmcid: 6471808
Impellizzeri D, Siracusa R, Cordaro M, Peritore AF, Gugliandolo E, D'amico R, Fusco R, Crupi R, Rizzarelli E, Cuzzocrea S et al (2020) Protective effect of a new hyaluronic acid -carnosine conjugate on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis. Biomed Pharmacother 125:110023. https://doi.org/10.1016/j.biopha.2020.110023
Szabó C, Virág L, Cuzzocrea S, Scott GS, Hake P, O’Connor MP, Zingarelli B, Salzman A, Kun E (1998) Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci U S A 95(7):3867–3872. https://doi.org/10.1073/pnas.95.7.3867
doi: 10.1073/pnas.95.7.3867
pubmed: 9520459
pmcid: 19929
Negri L, Lattanzi R, Tabacco F, Scolaro B, Rocchi R (1998) Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration. Br J Pharmacol 124:1516–1522. https://doi.org/10.1038/sj.bjp.0701971
doi: 10.1038/sj.bjp.0701971
pubmed: 9723966
pmcid: 1565530
Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77–88. https://doi.org/10.1016/0304-3959(88)90026-7
doi: 10.1016/0304-3959(88)90026-7
pubmed: 3340425
Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Peli A, Morittu VM, Britti D, Cuzzocrea S (2013) Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res Ther 15:4055. https://doi.org/10.1186/ar4382
doi: 10.1186/ar4382
Luczaj W, Jarocka-Karpinska I, Sierakowski S, Andrisic L, Zarkovic N, Skrzydlewska E (2014) Lipid peroxidation in rheumatoid arthritis; consequences and monitoring. Free Radic Biol Med 75(Suppl 1):S49. https://doi.org/10.1016/j.freeradbiomed.2014.10.816
doi: 10.1016/j.freeradbiomed.2014.10.816
pubmed: 26461394
Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358. https://doi.org/10.1016/0003-2697(79)90738-3
doi: 10.1016/0003-2697(79)90738-3
pubmed: 36810
Choi IA, Choi JY, Jung S, Basri F, Park S, Lee EY (2017) GV1001 immunotherapy ameliorates joint inflammation in a murine model of rheumatoid arthritis by modifying collagen-specific T-cell responses and downregulating antigen-presenting cells. Int Immunopharmacol 46:186–193. https://doi.org/10.1016/j.intimp.2017.03.011
doi: 10.1016/j.intimp.2017.03.011
pubmed: 28314223
Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, Esposito E, Cuzzocrea S (2012) Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun 26:1310–1321. https://doi.org/10.1016/j.bbi.2012.07.021
doi: 10.1016/j.bbi.2012.07.021
pubmed: 22884901
Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, Thiemermann C (2003) Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 48:3544–3556. https://doi.org/10.1002/art.11351
doi: 10.1002/art.11351
pubmed: 14674008
Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3537–3545. https://doi.org/10.1172/jci36389
doi: 10.1172/jci36389
pubmed: 18982160
pmcid: 2575731
Liu T, Zhang L, Joo D, Sun SC (2017) NF-κB signaling in inflammation. Signal Transduct Target Ther 2:17023. https://doi.org/10.1038/sigtrans.2017.23 . Epub 2017 Jul 14. PMID: 29158945; PMCID: PMC5661633
Lattanzi R, Miele R (2022) Prokineticin-receptor network: mechanisms of regulation Life (Basel) 12(2):172. https://doi.org/10.3390/life12020172
doi: 10.3390/life12020172
pubmed: 35207461
Kurosaka D, Yasuda J, Yoshida K, Yasuda C, Toyokawa Y, Yokoyama T, Kingetsu I, Yamada A (2005) Kinetics of circulating endothelial progenitor cells in mice with type II collagen arthritis. Blood Cells Mol Dis 35:236–240. https://doi.org/10.1016/j.bcmd.2005.06.001
doi: 10.1016/j.bcmd.2005.06.001
pubmed: 16023391
Kurosaka D, Yoshida K, Yasuda J, Yasuda C, Noda K, Furuya K, Ukichi T, Kingetsu I, Joh K, Yamaguchi N et al (2007) The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. Scand J Rheumatol 36:434–441. https://doi.org/10.1080/03009740701605913
doi: 10.1080/03009740701605913
pubmed: 18092264
Beale K, Gardiner JV, Bewick GA, Hostomska K, Patel NA, Hussain SS, Jayasena CN, Ebling FJ, Jethwa PH, Prosser HM et al (2013) Peripheral administration of prokineticin 2 potently reduces food intake and body weight in mice via the brainstem. Br J Pharmacol 168:403–410. https://doi.org/10.1111/j.1476-5381.2012.02191.x
doi: 10.1111/j.1476-5381.2012.02191.x
pubmed: 22935107
Maftei D, Lattanzi R, Vincenzi M, Squillace S, Fullone MR, Miele R (2021) The balance of concentration between prokineticin 2β and prokineticin 2 modulates the food intake by STAT3 signaling. BBA Advances 1:100028. https://doi.org/10.1016/j.bbadva.2021.100028
Filippin LI, Vercelino R, Marroni NP, Xavier RM (2008) Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 152:415–422. https://doi.org/10.1111/j.1365-2249.2008.03634.x
doi: 10.1111/j.1365-2249.2008.03634.x
pubmed: 18422737
pmcid: 2453196